Business Wire

TRAXENS

3.6.2019 08:32:12 CEST | Business Wire | Press release

Share
Traxens to Showcase Its Multimodal Offering at Transport Logistic Exhibition in Munich

Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will be introducing its comprehensive solutions portfolio aimed at the maritime and rail freight industries at Transport Logistic (June 4-7, Munich).

Traxens’ solutions provide comprehensive, precise and timely data about cargo by tracking wagons and smart containers in transit anywhere in the world through dedicated sensors, an Internet-of-Things network and a customized portal. Traxens’ technology brings improved efficiency and security, greater transparency and enhanced asset utilization thanks to improved wagon, container and goods tracking, geolocalisation and ambient temperature monitoring.

The rail freight industry could enjoy the benefits of a number of rail projects Traxens has accomplished with partners. In co-operation with SNCF Logistics, Traxens has trialled a Digital Freight Train, where a number of smart wagons equipped with Traxens-boxes were successfully tracked on their way to European destinations as well as China. Accurate real-time data from the whole train led to improved efficiency as well as cost reductions.
In addition to this, Traxens also offers digital brake testing, which can bring up to thirty minutes time-saving on standard re-allocation processes, real-time alerts on the brake system and significantly reduced operational costs.

“Traxens’ offering for rail freight was instrumental in bringing transparency to our operations for the digital future. A great example is the digital brake test, which brings us significant time savings at reallocation processes, improved cost and operational efficiency thanks to real-time monitoring of brake systems en route, as well as enhanced work conditions,” said Marc Valette, innovation director, CFL multimodal.

Bertrand MINARY, Chief Innovation officer at Fret SNCF said: “ It is an absolute necessity to transport more goods via rail freight to preserve our planet. Improved efficiency and new services will convince customers to move more cargo on rail instead of road freight by 2030, as suggested by the European Rail Freight Forward initiative. In order to improve reliability, we worked together with Traxens on the Digital Freight Train. For SNCF Logistics, Traxens’ unique, easy-to-implement, innovative, affordable and energy-efficient solution is simply the best to achieve that.“

For the maritime sector, Traxens provides door-to-door data monitoring solutions for smart containers (both dry and reefers) and has already signed agreement with dozens of Beneficial Cargo Owners, such as Tesco Global.

“The Traxens unit has provided us with unprecedented insights into our container movements, supplier performance and landside operation. It has the potential to shape the way we can use reliable data driven insights to manage our end-to-end operation, take strategic action and ultimately reduce costs, waste and lead-times,” said Peter Downs, Senior Logistics Performance Manager, Global Logistics at Tesco Global.

Traxens will be present at Booth A3.628 at Transport Logistic in Munich (4-7 June).

About Traxens
Traxens generates, collects, consolidates, enriches and transforms logistics asset data into actionable insight for its clients in the maritime, rail and supply chain industries.
The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.
www.traxens.com

Contact:

PRESS: Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye